BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 29490947)

  • 1. Metabolic Determinants of Sensitivity to Phosphatidylinositol 3-Kinase Pathway Inhibitor in Small-Cell Lung Carcinoma.
    Makinoshima H; Umemura S; Suzuki A; Nakanishi H; Maruyama A; Udagawa H; Mimaki S; Matsumoto S; Niho S; Ishii G; Tsuboi M; Ochiai A; Esumi H; Sasaki T; Goto K; Tsuchihara K
    Cancer Res; 2018 May; 78(9):2179-2190. PubMed ID: 29490947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of PI3K/BMX Cell Survival Pathway Sensitizes to BH3 Mimetics in SCLC.
    Potter DS; Galvin M; Brown S; Lallo A; Hodgkinson CL; Blackhall F; Morrow CJ; Dive C
    Mol Cancer Ther; 2016 Jun; 15(6):1248-60. PubMed ID: 27197306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic Hallmarks for Purine Nucleotide Biosynthesis in Small Cell Lung Carcinoma.
    Tabata S; Umemura S; Narita M; Udagawa H; Ishikawa T; Tsuboi M; Goto K; Ishii G; Tsuchihara K; Ochiai A; Kobayashi SS; Soga T; Makinoshima H
    Mol Cancer Res; 2024 Jan; 22(1):82-93. PubMed ID: 37773022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and durability of benefit of mTOR inhibitors in a real-world cohort of patients with metastatic prostate cancer and PI3K pathway alterations.
    Eule CJ; Flaig TW; Wong K; Graf R; Lam ET
    Prostate Cancer Prostatic Dis; 2023 Mar; 26(1):188-193. PubMed ID: 36402814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multiplexed in¬†vivo approach to identify driver genes in small cell lung cancer.
    Lee MC; Cai H; Murray CW; Li C; Shue YT; Andrejka L; He AL; Holzem AME; Drainas AP; Ko JH; Coles GL; Kong C; Zhu S; Zhu C; Wang J; van de Rijn M; Petrov DA; Winslow MM; Sage J
    Cell Rep; 2023 Jan; 42(1):111990. PubMed ID: 36640300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting PEA3 transcription factors to mitigate small cell lung cancer progression.
    Shia DW; Choi W; Vijayaraj P; Vuong V; Sandlin JM; Lu MM; Aziz A; Marin C; Aros CJ; Sen C; Durra A; Lund AJ; Purkayastha A; Rickabaugh TM; Graeber TG; Gomperts BN
    Oncogene; 2023 Feb; 42(6):434-448. PubMed ID: 36509998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gedatolisib shows superior potency and efficacy versus single-node PI3K/AKT/mTOR inhibitors in breast cancer models.
    Rossetti S; Broege A; Sen A; Khan S; MacNeil I; Molden J; Kopher R; Schulz S; Laing L
    NPJ Breast Cancer; 2024 Jun; 10(1):40. PubMed ID: 38839777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of host glutamine anabolism enhances the sensitivity of small cell lung cancer to chemotherapy.
    Kodama M; Toyokawa G; Sugahara O; Sugiyama S; Haratake N; Yamada Y; Wada R; Takamori S; Shimokawa M; Takenaka T; Tagawa T; Kittaka H; Tsuruda T; Tanaka K; Komatsu Y; Nakata K; Imado Y; Yamazaki K; Okamoto I; Oda Y; Takahashi M; Izumi Y; Bamba T; Shimizu H; Yoshizumi T; Nakayama KI
    Cell Rep; 2023 Aug; 42(8):112899. PubMed ID: 37531252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrated omics and gene expression analysis identifies the loss of metabolite-metabolite correlations in small cell lung cancer.
    Yu L; Li K; Xu Z; Cui G; Zhang X
    Onco Targets Ther; 2018; 11():3919-3929. PubMed ID: 30013371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Electron transport chain inhibition increases cellular dependence on purine transport and salvage.
    Wu Z; Bezwada D; Cai F; Harris RC; Ko B; Sondhi V; Pan C; Vu HS; Nguyen PT; Faubert B; Cai L; Chen H; Martin-Sandoval M; Do D; Gu W; Zhang Y; Zhang Y; Brooks B; Kelekar S; Zacharias LG; Oaxaca KC; Patricio JS; Mathews TP; Garcia-Bermudez J; Ni M; DeBerardinis RJ
    Cell Metab; 2024 Jun; ():. PubMed ID: 38876105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PKM1 Confers Metabolic Advantages and Promotes Cell-Autonomous Tumor Cell Growth.
    Morita M; Sato T; Nomura M; Sakamoto Y; Inoue Y; Tanaka R; Ito S; Kurosawa K; Yamaguchi K; Sugiura Y; Takizaki H; Yamashita Y; Katakura R; Sato I; Kawai M; Okada Y; Watanabe H; Kondoh G; Matsumoto S; Kishimoto A; Obata M; Matsumoto M; Fukuhara T; Motohashi H; Suematsu M; Komatsu M; Nakayama KI; Watanabe T; Soga T; Shima H; Maemondo M; Tanuma N
    Cancer Cell; 2018 Mar; 33(3):355-367.e7. PubMed ID: 29533781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Podoplanin-positive cancer-associated fibroblast recruitment within cancer stroma is associated with a higher number of single¬†nucleotide variants in cancer cells in lung adenocarcinoma.
    Nakasone S; Mimaki S; Ichikawa T; Aokage K; Miyoshi T; Sugano M; Kojima M; Fujii S; Kuwata T; Ochiai A; Tsuboi M; Goto K; Tsuchihara K; Ishii G
    J Cancer Res Clin Oncol; 2018 May; 144(5):893-900. PubMed ID: 29511884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Echoes from Gaea, Poseidon, Hephaestus, and Prometheus: environmental risk factors for high blood pressure.
    Sharma P; Brook RD
    J Hum Hypertens; 2018 Sep; 32(8-9):594-607. PubMed ID: 29899375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishing quasi-steady state operations of microphysiological systems (MPS) using tissue-specific metabolic dependencies.
    Maass C; Dallas M; LaBarge ME; Shockley M; Valdez J; Geishecker E; Stokes CL; Griffith LG; Cirit M
    Sci Rep; 2018 May; 8(1):8015. PubMed ID: 29789564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dysregulation of de novo nucleotide biosynthetic pathway enzymes in cancer and targeting opportunities.
    Robinson AD; Eich ML; Varambally S
    Cancer Lett; 2020 Feb; 470():134-140. PubMed ID: 31733288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted Therapies and Biomarkers in Small Cell Lung Cancer.
    Taniguchi H; Sen T; Rudin CM
    Front Oncol; 2020; 10():741. PubMed ID: 32509576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic Diversity in Human Non-Small Cell Lung Cancer Cells.
    Chen PH; Cai L; Huffman K; Yang C; Kim J; Faubert B; Boroughs L; Ko B; Sudderth J; McMillan EA; Girard L; Chen D; Peyton M; Shields MD; Yao B; Shames DS; Kim HS; Timmons B; Sekine I; Britt R; Weber S; Byers LA; Heymach JV; Chen J; White MA; Minna JD; Xiao G; DeBerardinis RJ
    Mol Cell; 2019 Dec; 76(5):838-851.e5. PubMed ID: 31564558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion.
    Chalishazar MD; Wait SJ; Huang F; Ireland AS; Mukhopadhyay A; Lee Y; Schuman SS; Guthrie MR; Berrett KC; Vahrenkamp JM; Hu Z; Kudla M; Modzelewska K; Wang G; Ingolia NT; Gertz J; Lum DH; Cosulich SC; Bomalaski JS; DeBerardinis RJ; Oliver TG
    Clin Cancer Res; 2019 Aug; 25(16):5107-5121. PubMed ID: 31164374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A non-metabolic function of hexokinase 2 in small cell lung cancer: promotes cancer cell stemness by increasing USP11-mediated CD133 stability.
    Wang J; Shao F; Yang Y; Wang W; Yang X; Li R; Cheng H; Sun S; Feng X; Gao Y; He J; Lu Z
    Cancer Commun (Lond); 2022 Oct; 42(10):1008-1027. PubMed ID: 35975322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PFKFB3 regulates cancer stemness through the hippo pathway in small cell lung carcinoma.
    Thirusangu P; Ray U; Sarkar Bhattacharya S; Oien DB; Jin L; Staub J; Kannan N; Molina JR; Shridhar V
    Oncogene; 2022 Aug; 41(33):4003-4017. PubMed ID: 35804016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.